Description:
Corrects: MMWR Morb Mortal Wkly Rep. 2015 May 15; 64(18): 500–504.
In the report, “Controlling the Last Known Cluster of Ebola Virus Disease — Liberia, January–February 2015, the author list should read as follows: Tolbert Nyenswah1, Mosoka Fallah1, Sonpon Sieh1, Karsor Kollie1, Moses Badio1, Alvin Gray1, Priscilla Dilah1, Marnijina Shannon1, Stanley Duwor1, Chikwe Ihekweazu2, Thierry Cordier-Lasalle2, Shivam A. Shinde2, Esther Hamblion2, Gloria Davies-Wayne2, Murugan Ratnesh2, Christopher Dye2, Jonathan S. Yoder3, Peter McElroy3, Brooke Hoots3, Athalia Christie3, John Vertefeuille3, Sonja J. Olsen3, A. Scott Laney3, Joyce J. Neal3, Sirin Yaemsiri3, Thomas R. Navin3, Stewart Coulter3, Paran Pordell3, Terrence Lo3, Carl Kinkade3, Frank Mahoney3
Corrects: MMWR Morb Mortal Wkly Rep. 2015 Jun 12; 64(22): 608–612.
In the report, “Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015,” on page 610, the fifth paragraph should read as follows: “In four clinical tri- als (9–11,13) a total of 2,557 subjects received at least 1 dose of MenB-FHbp (21); no serious adverse events considered by the study investigator to be related (or possibly related) to the vaccine were reported. In three additional studies (12) (Pfizer, unpublished data) with a total of 7,251 sub- jects receiving at least 1 dose of MenB-FHbp, four subjects reported seven serious adverse events that were considered by the study investigator to be related (or possibly related) to the vaccine.§ All vaccine-related serious adverse events resolved without sequelae. No increased risk for any specific serious adverse event considered to be clinically significant was iden- tified in any of the studies. No deaths were considered to be related to MenB-FHbp. The most common solicited adverse reactions observed in the 7 days after receipt of MenB-FHbp in the clinical trials were pain at the injection site, fatigue, headache, myalgia, and chills (21).”
Corrects: MMWR Morb Mortal Wkly Rep. 2015 Jul 24; 64(28): 753–757.
In the report, “Launch of a Nationwide Hepatitis C Elimination Program — Georgia, April 2015,” on page 755, the second sentence should read, “MoLHSA partnered with Gilead Sciences, a pharmaceutical manufacturer that agreed to support the program by providing an initial 5,000 courses of the antiviral medications sofosbuvir (Sovaldi), followed by 20,000 treatment courses of ledipasvir-sofosbuvir (Harvoni) annually at no cost.
[PDF-134.47 KB]
